Knights of Columbus Asset Advisors LLC Invests $1.10 Million in Blueprint Medicines Co. (NASDAQ:BPMC)

Knights of Columbus Asset Advisors LLC acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 12,652 shares of the biotechnology company's stock, valued at approximately $1,104,000.

Several other large investors have also made changes to their positions in BPMC. Quarry LP purchased a new stake in Blueprint Medicines in the 3rd quarter worth $32,000. R Squared Ltd acquired a new position in shares of Blueprint Medicines during the 4th quarter worth about $51,000. Asset Management One Co. Ltd. acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth approximately $88,000. Van ECK Associates Corp raised its stake in Blueprint Medicines by 48.2% in the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock valued at $97,000 after purchasing an additional 363 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in Blueprint Medicines in the 3rd quarter valued at $108,000.

Insider Transactions at Blueprint Medicines

In related news, Director Jeffrey W. Albers sold 5,000 shares of the company's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $102.28, for a total transaction of $511,400.00. Following the completion of the sale, the director now directly owns 157,557 shares of the company's stock, valued at approximately $16,114,929.96. This represents a 3.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kate Haviland sold 1,446 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the sale, the chief executive officer now owns 149,378 shares of the company's stock, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 31,608 shares of company stock valued at $3,319,587 over the last three months. 4.21% of the stock is owned by corporate insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on BPMC shares. Scotiabank initiated coverage on shares of Blueprint Medicines in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 target price for the company. Wolfe Research assumed coverage on Blueprint Medicines in a report on Tuesday, March 18th. They issued an "outperform" rating for the company. JPMorgan Chase & Co. boosted their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. HC Wainwright reaffirmed a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Finally, Piper Sandler lifted their price target on Blueprint Medicines from $109.00 to $119.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $124.95.

Blueprint Medicines Price Performance

NASDAQ BPMC traded down $0.99 on Thursday, reaching $89.73. 651,991 shares of the stock traded hands, compared to its average volume of 712,419. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90. The company has a market cap of $5.73 billion, a price-to-earnings ratio of -83.08 and a beta of 0.58. The firm's fifty day simple moving average is $98.84 and its 200 day simple moving average is $93.95. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, research analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.